JPRN-UMIN000000748
已完成
2 期
A Randomized Multicenter Phase2 Trial of Neoadjuvant Paclitaxel followed by Fluorouracil,Epirubin,and Cyclophosphamide(FEC)with or without Estrogen Deprivation by LH-RH agonist or Aromatase Inhibitor in Breast Cancer larger than 2 cm. - A Randomized Multicenter Phase2 Trial of Neoadjuvant Paclitaxel followed by Fluorouracil,Epirubin,and Cyclophosphamide(FEC)with or without Estrogen Deprivation by LH-RH agonist or Aromatase Inhibitor in Breast Cancer larger than 2cm. (NACED Randomized Multicenter Phase2 Trial)
THE FIRST0 个研究点目标入组 120 人2007年6月30日
概览
- 阶段
- 2 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Breast Cancer
- 发起方
- THE FIRST
- 入组人数
- 120
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
研究者
入排标准
入选标准
- 未提供
排除标准
- •Exclusion Criteria 1\)Previous history of treatment with taxol, Anthracyclines and hormonal treatment. 2\)Infection, uncontrollable diabetes mellitus, severe heart disease, angina with poor control, myocardial infarction within 6 months, active ulcers, multiple cancers, severe neuropathy or any other severe complications. 3\)interstitial pneumonia and lung fibrous disease which needs treatment. 4\)liver cirrhosis. 5\)stage\-4 disease with metastasis. 6\)Pleural effusion, ascites, pericardial effusion. 7\)Coagulopathy including DIC. Pregnancy , possibility of pregnancy and breast feeding. 8\)History of severe allergic reactions. 9\)allergy to Clemophor. 10\)allergic to TXL, 5FU, EpiADM, CPM, LHRH\-A(premenopausal), exemestan (postmenopausal). 11\)allergic to alcohol. 12\)active multiple malignancies. 13\)patients judged to be inadequate to accrue
结局指标
主要结局
未指定
相似试验
终止
2 期
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast CancerLocally Advanced Breast CancerNCT03329378Icahn School of Medicine at Mount Sinai7
Unknown
2 期
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric CancerGastric CancerNeoadjuvant TherapyNCT04062058Jing Jin, M.D.82
终止
2 期
Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)NCT06114940Jinling Hospital, China17
Unknown
2 期
A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without CetuximabRectal CancerNCT00795301National University Hospital, Singapore74
进行中(未招募)
2 期
A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer2024-513957-55-00CatalYm GmbH31